Diamonds and Dogs
Novavax (NVAX) jumps 25% on federal funding. The biotech firm received $1.6 billion from the federal government to accelerate their COVID-19 vaccine development program. The funds will be used to complete late-stage clinical development of its vaccine candidate for Phase 3 trials and scale up manufacturing aiming to deliver 100 million doses of the vaccine, as early as year-end.
Paychex (PAYX) lower following earnings. Paychex is lower by a percent but continues to make money earning 61 cents per share as sales fell 6.7% to $915.1 million, ahead of estimates. The company ended the quarter with $1.0 billion in cash and $801.9 million in debt. Management believes their cash and cash flow will support business operations, capital purchases, share repurchases, and dividend payments for the foreseeable future.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.